Exemestane acts as an irreversible steroidal aromatase inactivator for endocrine therapy. The conversion of androgens into estrogens is blocked, significantly lowering the circulating hormone levels required for various targeted therapeutic outcomes.
Targeting aromatase enzymes, Exemestane reduces estrogen synthesis to help manage hormone-dependent conditions. Classified as a steroidal aromatase inhibitor, the molecule mimics the natural substrate while permanently deactivating the enzyme. It appears as the active compound in several generic and branded products, most notably the tablet sold under the name Aromasin. In Singapore, health-authority reviews list it among agents indicated for post-menopausal breast cancer therapy.
Found in the oral tablet marketed as Aromasin, this compound is supplied in 25 mg film-coated tablets. Manufacturers also produce identical strength tablets for generic distribution, meeting the Health Sciences Authority’s specifications. The product can be dispensed in blister packs or bottle containers, each designed to protect the dosage from moisture. Whether branded or generic, the formulation delivers the active substance systemically after ingestion.
Addressing estrogen-driven breast tissue growth, Exemestane finds use in post-menopausal hormone-dependent breast cancer. It is also prescribed as part of endocrine therapy following surgery or radiation to lower recurrence risk. Some clinicians employ it for off-label management of estrogen-related gynecologic conditions, though clinical guidance varies. Patients typically fall into the adult post-menopausal demographic, where circulating estrogen levels are already low.
Blocking the conversion of androgens to estrogen, the substance lowers circulating estrogen concentrations. By reducing the hormonal stimulus, it helps slow the proliferation of estrogen-responsive cells. The inhibition is irreversible, meaning enzyme activity does not recover until new proteins are synthesized. This pharmacologic effect contributes to symptom control in the targeted conditions.
Mild nausea, fatigue, and occasional joint discomfort may appear during early treatment weeks. Most users experience these symptoms transiently, with intensity decreasing over time.
Rare cases of severe bone loss, blood clot formation, or liver enzyme elevation require immediate medical attention. Prompt evaluation is essential if such signs develop.
Pregnant individuals, people with known hypersensitivity to steroidal aromatase inhibitors, and those with uncontrolled liver disease should avoid exposure. Caution also applies to patients with a history of osteoporosis.
Alcohol, strong CYP-19 inhibitors, and certain cholesterol-lowering agents can alter the drug’s effectiveness. Review the medication package insert for a complete interaction list.
Storing the tablets in a cool, dry place preserves potency throughout the treatment course. Typical regimens span several months to years, depending on the clinical goal and physician recommendation. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Exemestane does not constitute medical advice; individual medicines like Aromasin differ in strength, formulation, and instructions; we assume no liability for clinical application; patients should examine their medication’s labeling and consult a licensed healthcare professional for personalized guidance.
